Table 1.
Baseline characteristics between bisoprolol and placebo groups.
| Characteristics | Bisoprolol (N = 57) | Placebo (N = 55) | P value |
|---|---|---|---|
| Age (years) | 62.5 ± 11.8 | 64.4 ± 13.1 | 0.416 |
| Male | 37 (67.3%) | 27 (50.9%) | 0.177 |
| BMI (kg/m2) | 21.5 ± 4.3 | 21.3 ± 4.1 | 0.876 |
| DM | 10 (18.2%) | 7 (13.2%) | 0.600 |
| DM requiring insulin therapy | 5 (9.1%) | 3 (5.7%) | 0.716 |
| Hypertension | 30 (54.5%) | 23 (43.4%) | 0.256 |
| History of stroke | 3 (5.5%) | 2 (3.8%) | 1.000 |
| Coronary artery disease | 4 (7.0%) | 4 (7.3%) | 1.000 |
| Heart failure | 0 (0%) | 0 (0%) | |
| LVEF (%) | 64.7 ± 8.3 | 67.3 ± 8.1 | 0.104 |
| ASA score | |||
| ASA I | 24 (42.1%) | 30 (54.5%) | 0.407 |
| ASA II | 26 (45.6%) | 19 (34.5%) | |
| ASA III | 7 (12.3%) | 6 (10.9%) | |
| Hemoglobin (gm/dL) | 11.8 ± 1.8 | 12.2 ± 2.5 | 0.411 |
| Creatinine (mg/dL) | 1.2 ± 1.2 | 1.1 ± 1.2 | 0.616 |
| Antiplatelet | 15 (27.3%) | 10 (18.9%) | 0.364 |
| Statin | 17 (30.9%) | 12 (22.6%) | 0.389 |
| ACEI/ARB | 6 (10.9%) | 6 (11.3%) | 1.000 |
| Median duration of preoperative assigned therapy (days) | 3 ± 4 | 4 ± 2 | 0.669 |
ACEI/ARB angiotensin converting enzyme inhibitor/Angiotensin receptor blocker, BMI body mass index, DM diabetes mellitus, hs-TNT high-sensitive troponin-T, LVEF left ventricular ejection fraction.